Pure Bioscience, Inc. reported financial results for the fiscal year ended July 31, 2026, showing a slight increase in net product sales but a widening net loss compared to the prior year.
For the fiscal year ended July 31, 2026, the company reported net product sales of $2,315,000. This figure represents a $117,000 increase from the $2,198,000 in sales recorded for the fiscal year ended July 31, 2025. The company attributed this growth to increased sales across its end-user network.
However, the company’s financial performance was impacted by higher operating expenses. The net loss for the fiscal year ended July 31, 2026, was $2.483 million. This is an increase from the net loss of $2.399 million reported in the prior fiscal year. The company noted that the prior year’s loss was partially offset by $175,000 received from the U.S. Government’s Employee Retention Tax Credit Program.
Excluding share-based compensation, the net loss for the fiscal year ended July 31, 2026, was $2.3 million. The company’s cash used in operations for the fiscal year ended July 31, 2026, was $1.97 million, compared to $2.0 million in the prior year.
On the balance sheet, the company reported total assets of $1,193,000 as of July 31, 2026, consisting of $569,000 in cash and cash equivalents, $334,000 in accounts receivable, and $193,000 in net inventories. Total liabilities were reported at $7,592,000, with $4,371,000 classified as current liabilities. This includes $3,381,000 in convertible notes payable to related parties, of which $1,015,000 was past due as of the reporting date.
Management stated that the company achieved year-over-year growth despite a challenging macro environment and disruptions in the food industry. The company noted that product penetration in the dairy industry has not met expectations due to slow customer adoption and industry consolidation. The company remains focused on reducing costs and strengthening its business development models.
